digestive tract disease
Conditions
Interventions
control group:Sufentanil in combination with propofol
experimental group 1:Esketamine in combination with propofol
experimental group 2:Afentanil in combination with propofol
Sponsors
The Central Hospital of Enshi Tujia and Miao Autonomous Prefesture
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 - 65 years; 2. Patients undergoing elective painless gastrointestinal ensoscopy; 3. ASA I-II grade; 4. No serious cardiovascular and cerebrovascular diseases, normal liver and kidney functions, and no other special medical history of anesthesia drug allergy. Patients with any of the following exclusion criteria were not eligible for this study; 5. Patients or their families have a full understanding of the purpose and significance of this trial, voluntarily participate in this clinical trial, and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. It is difficult to evaluate the efficacy of the patient's physical condition (such as patients with craniocerebral injury, possible intracranial hypertension, cerebral aneurysm, history of cerebrovascular accident, and history of central nervous system diseases); 2. Diabetic patients whose blood sugar has not been satisfactorily controlled (fasting blood sugar >= 11.1mmol/L during the screening period); 3. History of myocardial infarction and unstable angina pectoris within 6 months before the screening period; 4. Patients with bradycardia (heart rate = 160 mmHg during the screening period, and/or diastolic blood pressure >= 100 mmHg during the screening period, and systolic blood pressure 1.5 times the upper limit of normal value, APTT > 1.5 times the upper limit of normal value), with bleeding tendency (such as active peptic ulcer) or receiving thrombolytic or anticoagulation therapy; 8. Abnormal liver function, ALT and/or AST > 1.5 times the upper limit of normal; 9. Abnormal renal function, serum creatinine (Cr) and/or blood urea nitrogen (BUN) > 1.5 times the upper limit of normal; dialysis patients; 10. Allergic to the components or components of the test drug; 11. Women who are pregnant or breastfeeding; 12. Participate in clinical trials of other drugs within 3 months; 13. Patients with a history of hyperthyroidism; 14. Patients with a history of elevated intraocular pressure (such as glaucoma) or puncture eye injury; 15. Patients with a history of asthma; 16. Patients who are judged to have difficulty in airway management (modified Markov score grade IV).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| respiratory depression;hypotension;Modified Observer's Assessment Alert/ Sedation, MOAA/S;Intubation tolerance score;Onset time of anesthesia;Anesthesia recovery time;Hospital Discharge score;nausea;Vomit;Postoperative restlessness;polycardia;bradycardia;hypertension;Postoperative psychiatric adverse reactions; | — |
Countries
China
Contacts
Public ContactZhu Xianlin
The Central Hospital of Enshi Tujia and Miao Autonomous Prefesture
Outcome results
None listed